p53
Aileron Begins Treating p53-Mutated Breast Cancer Patients in Study of Chemo-Protective Drug
The trial will explore whether ALRN-6924 prevents toxicity in patients receiving neoadjuvant chemotherapy treatment.
Affini-T Therapeutics Raises $175M in Financing Round
The company will use the funding to advance its T-cell receptor discovery platform and bring TCR therapy programs for solid tumors into the clinic.
Rain Therapeutics Begins Basket Trial Evaluating Milademetan for MDM2-Amplified Solid Tumors
The Phase II MANTRA-2 trial will enroll roughly 65 patients with tumors harboring wild-type p53 and a prespecified minimum MDM2 gene copy number.
Athenex Garners Rights to NCI-Discovered TCRs for Cell Therapies Development in Solid Tumors
The deal with NCI gives Athenex rights to develop cell therapies expressing TCRs discovered at the institute that target antigens in p53-, KRAS-, and EGFR-mutated solid cancers.
Aileron Therapeutics Begins Phase Ib Trial of Chemoprotective Drug in p53-Mutated NSCLC
The trial will explore whether ALRN-6924 can protect healthy cells and reduce toxicity from treatment with chemotherapy.
Aug 14, 2020
Jul 13, 2020